-
Product Insights
NewMerkel Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Merkel Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, ultraviolet exposure, and immune suppression. Symptoms include painless nodules on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and...
-
Product Insights
NewBasal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024
Empower your strategies with our Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024 report and make more profitable business decisions. Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include a waxy bump; a scaly, brown, or flesh-colored patch; or a white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery. The Basal Cell Carcinoma (Basal Cell Epithelioma) drugs in...
-
Product Insights
NewGorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) – Drugs In Development, 2024
Empower your strategies with our Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Gorlin syndrome, also known as basal cell nevous syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment...
-
Product Insights
NewAcral Lentiginous Melanoma – Drugs In Development, 2024
Empower your strategies with our Acral Lentiginous Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Acral lentiginous melanoma (ALM), also sometimes referred to as, simply, acral melanoma, is melanoma occurring on the hands and feet (palms, soles, fingers, toes, and nail units). This is is a subtype of cutaneous malignant melanoma. The condition can develop in normal-appearing skin or within an existing mole. It is comprised of malignant melanocytes, which can become invasive with time. The...
-
Product Insights
NewNonmelanomatous Skin Cancer – Drugs In Development, 2024
Empower your strategies with our Nonmelanomatous Skin Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nonmelanoma skin cancer comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), originating from skin cells other than melanocytes. Linked to sun exposure, these cancers often appear on sun-exposed areas. BCC, the most prevalent, usually presents as a pearly bump or a sore that doesn't heal. SCC may appear as a scaly patch or a firm, red nodule. While rarely...
-
Sector Analysis
Melanoma – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Melanoma–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional melanoma therapies was $5.5 billion in 2021. The growing aging population, leading to an increased diagnosed incidence of melanoma across age groups will drive market growth during the forecast period. Melanoma–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More About the Melanoma–Cell and Gene Therapies 15-Market Forecast Download a Free Report Sample The...
-
Sector Analysis
Melanoma – Global Drug Forecast and Market Analysis to 2029
Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body. Although melanoma has high survivability, it remains a significant health risk around the world. Where possible, melanoma is treated with surgery, with stage III patients likely to receive adjuvant therapy with either PD-1 inhibitors; BMS’ Opdivo or Merck & Co’s Keytruda or, if BRAF V600-positive, Novartis’ BRAF/MEK inhibitor combination Tafinlar + Mekinist. Metastatic...